TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/09/2026
Back to search
Official data from USPTO
TEVA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
57
Latest update
03/11/2026
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
02/28/2017
Registration date
12/15/2020
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/15/2020
Last transaction
03/11/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/21/2020
First use in commerce
09/21/2020
Drawing code
3
Owner type
99
Owner location
Jerusalem, IL
Examiner
MICHELI, ANGELA M
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a line design that begins at the bottom center and rises up to the center right side. In the bottom right hand corner is the word TEVA with the letter v formed by 2 leaf shapes.
Holders and representatives
Holders
Teva Pharmaceutical Industries Limited
Representatives
Lori Wolfe Teva Pharmaceuticals USA, Inc.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that supportencourage and promote bone strength; Pharmaceutical preparations that supportencourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparationsinjectable contraceptives; Pharmaceutical preparationscontraceptive preparations; Pharmaceutical preparationsfertility enhancement preparations; Pharmaceutical preparationshormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system
Publications
History of USPTO decisions and trademark events.
57 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/09/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/09/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/09/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/09/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/15/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
12/15/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/10/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/09/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
11/05/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/05/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
11/05/2020
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
11/05/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/30/2020
IUAF
USE AMENDMENT FILED
10/20/2020
EISU
TEAS STATEMENT OF USE RECEIVED
10/20/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/22/2020
EX5G
SOU EXTENSION 5 GRANTED
08/21/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/18/2020
EXT5
SOU EXTENSION 5 FILED
08/13/2020
EEXT
SOU TEAS EXTENSION RECEIVED
08/13/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/29/2020
EX4G
SOU EXTENSION 4 GRANTED
02/19/2020
EXT4
SOU EXTENSION 4 FILED
02/19/2020
EEXT
SOU TEAS EXTENSION RECEIVED
02/19/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/19/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/15/2019
EX3G
SOU EXTENSION 3 GRANTED
08/13/2019
EXT3
SOU EXTENSION 3 FILED
08/13/2019
EEXT
SOU TEAS EXTENSION RECEIVED
08/13/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/15/2019
EX2G
SOU EXTENSION 2 GRANTED
02/13/2019
EXT2
SOU EXTENSION 2 FILED
02/13/2019
EEXT
SOU TEAS EXTENSION RECEIVED
02/13/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/15/2018
EX1G
SOU EXTENSION 1 GRANTED
08/13/2018
EXT1
SOU EXTENSION 1 FILED
08/13/2018
EEXT
SOU TEAS EXTENSION RECEIVED
08/13/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/20/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/26/2017
PUBO
PUBLISHED FOR OPPOSITION
12/26/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/06/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/17/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
11/17/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/17/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
11/17/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/17/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/14/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/14/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/14/2017
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
05/26/2017
GPRA
PRIORITY ACTION E-MAILED
05/26/2017
CPRA
PRIORITY ACTION WRITTEN
05/26/2017
DOCK
ASSIGNED TO EXAMINER
05/23/2017
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/08/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/07/2017
NWAP
NEW APPLICATION ENTERED
03/03/2017
Continuous trademark protection
Get notified about every new filing that threatens TEVA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.